WO1997048370A3 - Vaccines comprising synthetic genes - Google Patents

Vaccines comprising synthetic genes Download PDF

Info

Publication number
WO1997048370A3
WO1997048370A3 PCT/US1997/010517 US9710517W WO9748370A3 WO 1997048370 A3 WO1997048370 A3 WO 1997048370A3 US 9710517 W US9710517 W US 9710517W WO 9748370 A3 WO9748370 A3 WO 9748370A3
Authority
WO
WIPO (PCT)
Prior art keywords
synthetic
codons
polynucleotides
expression
molecules
Prior art date
Application number
PCT/US1997/010517
Other languages
French (fr)
Other versions
WO1997048370A2 (en
Inventor
John W Shiver
Mary Ellen Davies
Daniel C Freed
Margaret A Liu
Helen C Perry
Original Assignee
Merck & Co Inc
John W Shiver
Mary Ellen Davies
Daniel C Freed
Margaret A Liu
Helen C Perry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614942.2A external-priority patent/GB9614942D0/en
Priority claimed from GBGB9614943.0A external-priority patent/GB9614943D0/en
Application filed by Merck & Co Inc, John W Shiver, Mary Ellen Davies, Daniel C Freed, Margaret A Liu, Helen C Perry filed Critical Merck & Co Inc
Priority to EP97931230A priority Critical patent/EP0912607A2/en
Priority to JP10503267A priority patent/JP2000516445A/en
Priority to AU34918/97A priority patent/AU728422B2/en
Publication of WO1997048370A2 publication Critical patent/WO1997048370A2/en
Publication of WO1997048370A3 publication Critical patent/WO1997048370A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Synthetic polynucleotides comprising a DNA sequence encoding a peptide or protein are provided. The DNA sequence of the synthetic polynucleotides comprise codons optimized for expression in a nonhomologous host. The invention is exemplified by synthetic DNA molecules encoding HIV env as well as modifications of HIV env. The codons of the synthetic molecules include the projected host cell's preferred codons. The synthetic molecules provide preferred forms of foreign genetic material. The synthetic molecules may be used as a polynucleotide vaccine which provides immunoprophylaxis against HIV infection through neutralizing antibody and cell-mediated immunity. This invention provides polynucleotides which, when directly introduced into a vertebrate in vivo, including mammals such as primates and humans, induces the expression of encoded proteins within the animal.
PCT/US1997/010517 1996-06-21 1997-06-17 Vaccines comprising synthetic genes WO1997048370A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97931230A EP0912607A2 (en) 1996-06-21 1997-06-17 Vaccines comprising synthetic genes
JP10503267A JP2000516445A (en) 1996-06-21 1997-06-17 Vaccines containing synthetic genes
AU34918/97A AU728422B2 (en) 1996-06-21 1997-06-17 Vaccines comprising synthetic genes

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US2016596P 1996-06-21 1996-06-21
US2016696P 1996-06-21 1996-06-21
US60/020,166 1996-06-21
US60/020,165 1996-06-21
GB9614942.2 1996-07-16
GBGB9614942.2A GB9614942D0 (en) 1996-07-16 1996-07-16 Synthetic HIV ENV genes
GBGB9614943.0A GB9614943D0 (en) 1996-07-16 1996-07-16 Vaccines comprising synthetic genes
GB9614943.0 1996-07-16

Publications (2)

Publication Number Publication Date
WO1997048370A2 WO1997048370A2 (en) 1997-12-24
WO1997048370A3 true WO1997048370A3 (en) 1998-03-26

Family

ID=27451496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/010517 WO1997048370A2 (en) 1996-06-21 1997-06-17 Vaccines comprising synthetic genes

Country Status (5)

Country Link
EP (1) EP0912607A2 (en)
JP (1) JP2000516445A (en)
AU (1) AU728422B2 (en)
CA (1) CA2258568A1 (en)
WO (1) WO1997048370A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU778809B2 (en) 1999-03-29 2004-12-23 Statens Serum Institut Method for producing a nucleotide sequence construct with optimised codons for an HIV genetic vaccine based on primary, early HIV isolate and synthetic envelope BX08 constructs
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
JP2003530307A (en) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド Adenovirus HIV vaccine with gag gene
EP1228237A1 (en) 1999-11-01 2002-08-07 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
DE10053781B4 (en) * 2000-10-30 2008-07-03 Geneart Ag Nuclear export reporter system
ES2340532T3 (en) 2001-06-05 2010-06-04 Curevac Gmbh MRNA WITH AN INCREASED G / C CONTENT THAT CODIFIES FOR A BACTERIAL ANTIGEN AND USING THE SAME.
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
AU2003235707A1 (en) * 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
US7901690B2 (en) 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
US7399467B2 (en) 2003-12-23 2008-07-15 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
CA2946751A1 (en) 2014-04-23 2015-10-29 Modernatx, Inc. Nucleic acid vaccines
CN112735525B (en) * 2021-01-18 2023-12-26 苏州科锐迈德生物医药科技有限公司 mRNA sequence optimization method and device based on divide-and-conquer method

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
WO1995020660A2 (en) * 1994-01-27 1995-08-03 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
WO1996021356A1 (en) * 1995-01-13 1996-07-18 Vanderbilt University Methods and compositions for inducing mucosal immune responses
JPH08198774A (en) * 1995-01-20 1996-08-06 Terumo Corp Dna vaccine
WO1997011086A1 (en) * 1995-09-22 1997-03-27 The General Hospital Corporation High level expression of proteins
WO1997031115A2 (en) * 1996-02-22 1997-08-28 Merck & Co., Inc. Synthetic hiv genes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
WO1995020660A2 (en) * 1994-01-27 1995-08-03 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
WO1996021356A1 (en) * 1995-01-13 1996-07-18 Vanderbilt University Methods and compositions for inducing mucosal immune responses
JPH08198774A (en) * 1995-01-20 1996-08-06 Terumo Corp Dna vaccine
WO1997011086A1 (en) * 1995-09-22 1997-03-27 The General Hospital Corporation High level expression of proteins
WO1997031115A2 (en) * 1996-02-22 1997-08-28 Merck & Co., Inc. Synthetic hiv genes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B. WANG ET AL.: "Gene inoculation generates immune responses against human immunodeficiency virus type 1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, 1 May 1993 (1993-05-01), WASHINGTON US, pages 4156 - 4160, XP000608482 *
DATABASE WPI Section Ch Week 9641, Derwent World Patents Index; Class B04, AN 96-408330, XP002036840 *
K. OKUDA ET AL.: "Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV typr 1 env and rev gene products", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, no. 8, August 1995 (1995-08-01), pages 933 - 943, XP002036839 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA

Also Published As

Publication number Publication date
JP2000516445A (en) 2000-12-12
EP0912607A2 (en) 1999-05-06
AU3491897A (en) 1998-01-07
WO1997048370A2 (en) 1997-12-24
CA2258568A1 (en) 1997-12-24
AU728422B2 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
WO1997048370A3 (en) Vaccines comprising synthetic genes
WO2001062794A3 (en) 18607, a human calcium channel
WO1998034640A3 (en) Synthetic hiv gag genes
CA2158455A1 (en) Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
NZ331161A (en) Synthetic HIV genes encoding envelope (env) proteins
WO2001014416A3 (en) Synthetic papillomavirus genes optimized for expression in human cells
WO2002000722A3 (en) Human calcium channels (48000; 52920) and uses thereof
WO2002006302A3 (en) 16816 and 16839, novel human phospholipase c molecules and uses therefor
WO2002000718A3 (en) A human calcium channel protein and uses thereof
WO2002026803A3 (en) 22108 and 47916, novel human thioredoxin family members and uses thereof
WO1998042847A3 (en) Papilloma virus main capsid protein and the use thereof in diagnosis, therapy and vaccination
WO1999009177A3 (en) Papilloma virus, agents for the detection thereof and for the therapy of the diseases caused by said virus
WO2001075076A3 (en) 33167, a novel human hydrolase and uses therefor
WO2001066764A3 (en) 16835, a human phospholipase c and uses thereof
WO2002029042A3 (en) 48120, 23479, and 46689, novel human hydrolases and uses thereof
WO2001077329A3 (en) Human twik molecules and uses thereof
WO2002008395A3 (en) Putative human methyltransferase family member and uses thereof
WO2002050256A8 (en) 53010, a human carboxylesterase family member and uses thereof
WO2002026804A3 (en) 84241, a human ring finger family member and uses thereof
WO2002026983A3 (en) 56115, a novel human twik potassium channel and uses therefor
WO2003048188A3 (en) 15603, a human ion channel family member
WO2002059314A3 (en) A human melanoma associated antigen and uses therefor
WO2002016568A3 (en) 46863, a human methyltransferase and uses thereof
WO2002038773A3 (en) A human phospholipase c and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1997931230

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2258568

Country of ref document: CA

Ref country code: CA

Ref document number: 2258568

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997931230

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997931230

Country of ref document: EP